Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Patricia Chevez-Barrios, M.D.

Patricia Chevez-Barrios, M.D.

 

Patricia Chévez-Barrios, M.D.

Associate Member
Director, Ocular Pathology Research Laboratory
Director, The Methodist Hospital Research Institute Summer Student Program
The Methodist Hospital Research Institute
Director, Ophthalmic Pathology Program
Department of Pathology and Genomic Medicine
The Methodist Hospital Physician Organization
Co-Director, Retinoblastoma Center of Houston
Professor of Pathology and Laboratory Medicine and Ophthalmology
Weill Cornell Medical College of Cornell University

E-mail: pchevez-barrios@houstonmethodist.org
Phone: 713-441-6484


Education

B.S.   Colegio de Ciencias y Humanidades, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico
M.D.   Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

Postdoctoral Training

Internship, Department of Pathology, General Hospital of Mexico, Mexico City, Mexico
Ophthalmology Residency, Luis Sanchez Bulnes Hospital, Coyoacan, Mexico
Anterior Segment, Surgery Fellowship, Luis Sanchez Bulnes Hospital, Asociacion para Evitar la Ceguera en Mexico, Coyoacan, Mexico
Ophthalmic Pathology Fellowship, Luis Sanchez Bulnes Hospital, Asociacion para Evitar la Ceguera en Mexico, Coyoacan, Mexico
Ophthalmic Pathology Fellowship, Cullen Eye Institute, Baylor College of Medicine, Houston, TX
Retina and Vitreous Fellowship, Department of Ophthalmology, University of Texas Medical School, Houston, TX
Anatomic and Clinical Pathology Residency, Affiliated Hospitals Residency Program, Baylor College of Medicine, Houston, TX

 

Biography

After finishing all seven of her postdoctoral training programs, Dr. Chévez-Barrios joined the faculty of the Baylor College of Medicine in 1996 as an Assistant Professor in the Department of Pathology, with a secondary appointment in the Department of Ophthalmology. She became a Clinical Assistant Professor in the Department of Ophthalmology there in 2004, and received the Fulbright & Jaworski LLP Award for Faculty Excellence in Teaching and Evaluation and became Associate Member of the Cell and Gene Therapy Center that same year. She has current appointments of adjunct professor in the Department of Pathology at The University of Texas MD Anderson Cancer Center and Department of Ophthalmology at the Baylor College of Medicine. Dr. Chévez- Barrios assumed her current positions at Methodist in 2004.

Description of Research

The main research interest of Dr. Chévez-Barrios and her laboratory is the study of retinoblastoma, including cancer stem cells, suicide gene therapy for retinoblastoma, the study of metastatic properties of retinoblastoma and preclinical models of the tumor. Other topics of interest are ocular gene therapy, cataractogenesis, vascular proliferation in hypoxic ocular diseases and corneal diseases. Dr. Chevez-Barrios’ laboratory is currently participating in the project of gene therapy for Retinoblastomas in collaboration with the Texas Children’s Cancer Center and the Center for Gene Therapy of Texas Children's Hospital, and Baylor College of Medicine. Pre-clinical studies and a phase 1 clinical trial of vitreous seed of retinoblastoma have been completed. The phase II clinical trial is in preparation. Dr. Chevez-Barrios is a committee member responsible of evaluating all enucleated eyes from the prospective multicenter study of the ARET0332 Children’s Oncology Group protocol on “A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy.”

Dr. Chevez-Barrios is also interested in the biological differences between retinoblastoma cell lines that have the capability of producing metastasis, and those that behave less aggressively and remain as intraocular tumors.

Major Areas of Research

Retinoblastoma, metastasis, gene therapy, neovascularization.

Recent Publications

Wadhwa L, Bond WS, Perlaky L, Overbeek PA, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Embryonic Retinal Tumors in SV40 T-Ag Transgenic Mice Contain CD133+ Tumor-Initiating Cells. Invest Ophthalmol Vis Sci. 2012 Jun 8;53(7):3454-62.

Shinder R, Ramirez SA, Chévez-Barrios P, Gombos DS. Re: "retinoblastoma associated orbital cellulitis". Ophthal Plast Reconstr Surg. 2012 May;28(3):235-7.

Hwang CK, Aaberg TM Jr, Chevez-Barrios P, Verner-Cole E, Gombos DS, Paysse E, Chintagumpala M, Gao W, Grossniklaus HE. Residual intraretinal retinoblastoma after chemoreduction failure. Arch Ophthalmol. 2012 Feb;130(2):246-8.

Dhar SU, Chintagumpala M, Noll C, Chévez-Barrios P, Paysse EA, Plon SE. Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol. 2011 Nov;129(11):1428-34.

Bond WS, Wadhwa L, Perlaky L, Penland RL, Hurwitz MY, Hurwitz RL, Chèvez-Barrios P. Establishment and propagation of human retinoblastoma tumors in immune deficient mice. J Vis Exp. 2011 Aug 4;(54).

Blieden LS, Chévez-Barrios P, Yen MT. Herpes Simplex Vegetans Presenting as an Eyelid Mass. Ophthal Plast Reconstr Surg. 2011 May-Jun;27(3):e58-9.

Ildefonso CJ, Kong L, Leen A, Chai SJ, Petrochelli V, Chintagumpala M, Hurwitz MY, Chévez-Barrios P, Hurwitz RL. Absence of Systemic Immune Response to Adenovectors After Intraocular Administration to Children With Retinoblastoma. Mol Ther. 2010 Oct;18(10):1885-90.

Lee EI, Chévez-Barrios P, Soparkar CN. Metaplastic bone formation in the orbit. Ophthal Plast Reconstr Surg. 2010 Mar-Apr;26(2):120-2.

Matoba AY, Chevez-Barrios P, Jones DB. Atypical corneal immunoglobulin deposition in a patient with dysproteinemia. Cornea. 2010 Jan;29(1):105-7.

Chévez-Barrios P. The current face of ophthalmic pathology. Arch Ophthalmol. 2009 Aug;127(8):1048-9.

Raparia K, Chang CC, Chévez-Barrios P. Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens. Arch Pathol Lab Med. 2009 Aug;133(8):1233-7.

Sastre X, Chantada GL, Doz F, Wilson MW, de Davila MT, Rodríguez-Galindo C, Chintagumpala M, Chévez-Barrios P; International Retinoblastoma Staging Working Group. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009 Aug;133(8):1199-202.

Chévez-Barrios P. The current face of ophthalmic pathology. Arch Pathol Lab Med. 2009 Aug;133(8):1195-6.

Rodriguez-Galindo C, Wilson MW, Chantada G, Fu L, Qaddoumi I, Antoneli C, Leal-Leal C, Sharma T, Barnoya M, Epelman S, Pizzarello L, Kane JR, Barfield R, Merchant TE, Robison LL, Murphree AL, Chevez-Barrios P, Dyer MA, O'Brien J, Ribeiro RC, Hungerford J, Helveston EM, Haik BG, Wilimas J. Retinoblastoma: one world, one vision. Pediatrics. 2008 Sep;122(3):e763-70. Review.

Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008 Aug;126(8):1161-3.

Chantada GL, Doz F, Orjuela M, Qaddoumi I, Sitorus RS, Kepak T, Furmanchuk A, Castellanos M, Sharma T, Chévez-Barrios P, Rodriguez-Galindo C; on behalf of the International Retinoblastoma Staging Working Group: World disparities in risk definition and management of retinoblastoma: A report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008 Mar;50(3):692-4.

Gombos DS, Chevez-Barrios P. Current treatment and management of retinoblastoma. Curr Oncol Rep. 2007 Nov;9(6):453-8.

Chong EM, Coffee RE, Chintagumpala M, Hurwitz RL, Hurwitz MY, Chevez-Barrios P. Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med. 2006 Nov;130(11):1669-72.

Chevez-Barrios P. Frozen section diagnosis and indications in ophthalmic pathology. Arch Pathol Lab Med. 2005 Dec;129(12):1626-34.

Chévez-Barrios P, Chintagumpala M, Mieler W, Paysse E, Boniuk M, Kozinetz C, Hurwitz MY, Hurwitz RL. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol. 2005 Nov 1;23(31):7927-35